What is Aethlon Medical's market cap?

Aethlon Medical (AEMD) has a market capitalization of $1.5M and trades on NASDAQ.

Who are Aethlon Medical's competitors?

Aethlon Medical's key competitors include Nephros Inc., Cytosorbents Corp., Advanced Biomed Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Aethlon Medical partner with?

Aethlon Medical's notable partners include University of California, San Francisco, University of Pittsburgh, Vector Laboratories Inc., and others.

What subsidiaries does Aethlon Medical have?

Aethlon Medical's subsidiaries include Aethlon Medical Australia Pty Ltd.

Where is Aethlon Medical headquartered?

Aethlon Medical is headquartered in United States of America and employs approximately 14 people. It has been publicly traded since 1998.

Aethlon Medical

AEMD

Aethlon Medical is a clinical-stage medical therapeutic company developing the Hemopurifier, a proprietary immunotherapeutic device.

Market cap

$1.48M-38.0%

Table of contents

Earnings

Q1 2026 report

June 10, 2026

EPS$4.08Beat by $6.54

Read the full report

Next report

Aug 12, 2026 (In 2 weeks)

EPS estimate-$0.79

Competitors

By market cap

Haemonetics$3.6B+1.2%

Cerus$615.1M+137%

AngioDynamics$564.6M+52.4%

Nephros$37.2M-2.4%

ADV

Advanced Biomed Inc. Common Stock$23.7M+106%

Cytosorbents$22.6M-61.6%

ENDRA Life Sciences Inc.$6.1M+27.0%

Aethlon Medical$1.5M-42.4%

By revenue growth

AngioDynamics+9.5%

Cerus+1.8%

Haemonetics-2.0%

By net margin

Haemonetics13.31%—

Cerus-9.75%+4.9pp

AngioDynamics-11.48%+0.1pp

Profile

Aethlon Medical is a clinical-stage medical therapeutic company developing the Hemopurifier, a proprietary immunotherapeutic device. The technology utilizes a lectin-based system to bind and remove harmful extracellular vesicles and enveloped viruses from the bloodstream. The company's primary value proposition lies in addressing unmet needs in oncology, life-threatening infectious diseases, and organ transplantation.

Competitive position

Aethlon is a clinical-stage developer with Breakthrough Device designations from the FDA for specific oncology and viral indications, currently focused on establishing safety and efficacy data through human trials.

GeographiesUnited States, Australia, Canada, European Union, India

Customer segmentsHospitals, Clinical Trial Participants, Government Agencies

Business modelResearch and Development, Device Manufacturing

SuppliersGNA lectin suppliers, Base cartridge manufacturers, Diatomaceous earth suppliers, Dialysis machine manufacturers

CustomersTertiary care hospitals, Oncology clinics, Intensive care units, Organ transplant centers

CountryUnited States of America

Listed1998

Employees14.0

CEOJames Frakes

SectorHealthcare

IndustryMedical - Devices

Websiteaethlonmedical.com

FilingsSEC EDGAR

Questions, answered.

What is Aethlon Medical's market cap?: Aethlon Medical (AEMD) has a market capitalization of $1.5M and trades on NASDAQ.
Who are Aethlon Medical's competitors?: Aethlon Medical's key competitors include Nephros Inc., Cytosorbents Corp., Advanced Biomed Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Aethlon Medical partner with?: Aethlon Medical's notable partners include University of California, San Francisco, University of Pittsburgh, Vector Laboratories Inc., and others.
What subsidiaries does Aethlon Medical have?: Aethlon Medical's subsidiaries include Aethlon Medical Australia Pty Ltd.
Where is Aethlon Medical headquartered?: Aethlon Medical is headquartered in United States of America and employs approximately 14 people. It has been publicly traded since 1998.